Caxton Associates LLP Takes $1.36 Million Position in Novanta Inc. $NOVT

Caxton Associates LLP bought a new stake in Novanta Inc. (NASDAQ:NOVT) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,535 shares of the technology company’s stock, valued at approximately $1,362,000.

Several other hedge funds and other institutional investors also recently modified their holdings of NOVT. Gibbs Wealth Management grew its position in Novanta by 156.5% in the 1st quarter. Gibbs Wealth Management now owns 12,806 shares of the technology company’s stock worth $1,513,000 after purchasing an additional 7,814 shares during the last quarter. Sei Investments Co. grew its stake in shares of Novanta by 47.6% in the 1st quarter. Sei Investments Co. now owns 484,316 shares of the technology company’s stock worth $57,203,000 after purchasing an additional 156,263 shares during the last quarter. Group One Trading LLC acquired a new position in Novanta in the first quarter worth approximately $177,000. State of Wyoming acquired a new position in shares of Novanta in the 1st quarter worth $333,000. Finally, Cetera Investment Advisers increased its stake in Novanta by 39.3% in the 1st quarter. Cetera Investment Advisers now owns 13,950 shares of the technology company’s stock worth $1,648,000 after purchasing an additional 3,938 shares in the last quarter. Institutional investors and hedge funds own 98.35% of the company’s stock.

Insider Activity at Novanta

In other news, CEO Matthijs Glastra sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $150.43, for a total transaction of $1,128,225.00. Following the completion of the transaction, the chief executive officer directly owned 42,761 shares of the company’s stock, valued at approximately $6,432,537.23. This trade represents a 14.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.20% of the company’s stock.

Novanta Price Performance

NASDAQ:NOVT opened at $141.54 on Friday. The company has a fifty day moving average price of $155.63 and a 200 day moving average price of $140.10. The stock has a market cap of $5.34 billion, a P/E ratio of 102.57 and a beta of 1.67. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.56 and a quick ratio of 2.69. Novanta Inc. has a one year low of $98.27 and a one year high of $171.85.

Novanta (NASDAQ:NOVT) last released its earnings results on Monday, May 11th. The technology company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.03. Novanta had a net margin of 5.35% and a return on equity of 12.06%. The business had revenue of $257.71 million during the quarter, compared to analysts’ expectations of $253.40 million. During the same quarter last year, the company earned $0.74 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. Novanta has set its FY 2026 guidance at 3.500-3.650 EPS and its Q2 2026 guidance at 0.810-0.860 EPS. Analysts anticipate that Novanta Inc. will post 3.59 earnings per share for the current year.

Wall Street Analyst Weigh In

NOVT has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novanta in a research report on Wednesday, July 15th. Wall Street Zen upgraded Novanta from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Robert W. Baird set a $180.00 target price on Novanta in a report on Tuesday, June 9th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $180.00.

Novanta Profile

Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.

Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.